Business, energy, technology, markets and global industry news from Business News Today

VE303

PharmaDeviceNews VE303
Pharma & Biotech

Can Vedanta Biosciences turn microbiome therapeutics into a real prevention strategy for recurrent CDI and resistant infections?

Vedanta Biosciences unveiled VE303 and VE707 data at ESCMID 2026. Read why the microbiome strategy matters for CDI and resistant infections.

Read More
Representative image of microbiome therapeutics research as Vedanta Biosciences advances VE303 in Phase 3 for recurrent Clostridioides difficile infection, highlighting the growing stakes in standardized live biotherapeutic development.
Pharma & Biotech

Vedanta Biosciences keeps VE303 Phase 3 trial on track as interim review clears futility bar

Vedanta Biosciences kept VE303 Phase 3 on track after interim review. Read what this means for recurrent C. difficile treatment and microbiome drug development.

Read More